Kamuvudines

N/A

Report date: 2023/11/14 12:02:57
NMEFirst In Class

Base Information

Drug NameKamuvudines
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInflammasomes inhibitorsNACHT, LRR and PYD domains-containing protein 3 inhibitorsReverse transcriptase inhibitors
TargetsInflammasomesNACHT, LRR and PYD domains-containing protein 3Reverse transcriptase
Therapy Area/IndicationsGeographic AtrophyMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesInflammasome Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesInflammasome Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsGeographic AtrophyMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A